Research
Molecular
GLP-1 receptor agonists can exist stably in patients for a long time, overcoming the short half-life of natural GLP-1.
Practitioners can expect longer-lasting effects from GLP-1 receptor agonists compared to natural GLP-1.
StrongSupportsmedium confidence
To a certain extent, they overcome the problem of the short half-life of natural GLP-1 in vivo and can exist stably in patients for a long time.
Why this rating
The claim is based on a review of recent research progress.
Source
The Discovery and Development of Glucagon-Like Peptide-1Receptor Agonists
Haowen Fang et al. · Current Medicinal Chemistry · 2023
DOI 10.2174/0929867330666230416153301
reviewCited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →